Administration stated latest geopolitical occasions haven’t materially modified demand to this point, with healthcare and non-destructive testing largely steady and security-related inquiries trending “flat to optimistic.”
Varex expects modest gross-margin enchancment as older, higher-tariff stock clears—estimated at about 30–50 foundation factors if the present tariff regime holds—whereas pursuing supply-chain diversification and local-for-local manufacturing.
Profitability and progress levers embody an India manufacturing ramp (detectors ramping in H2 2026, tubes late 2026) concentrating on roughly $100 million of incremental radiographic income over ~two years, plus higher-margin photon-counting CT and cargo-inspection companies, and a debt refinancing that cuts coupons by ~175 foundation factors for ~$7–8 million annual curiosity financial savings (about $0.15–$0.16 EPS).
Executives from Varex Imaging (NASDAQ:VREX) stated latest geopolitical occasions and tariff volatility haven’t materially modified demand developments for the corporate to this point in 2026, whereas outlining expectations for incremental margin enchancment as prior tariff prices roll by stock and highlighting longer-term progress initiatives tied to India manufacturing growth, photon-counting CT detectors, and cargo inspection methods.
CEO Sunny Sanyal stated the corporate has restricted direct enterprise publicity within the Center East, together with minimal footprint in Iran, however is looking ahead to second-order impacts. He famous Varex makes use of vital ocean freight, although not by the Strait of Hormuz, and stated increased oil costs might increase commodity prices. “To date, we now have not seen something of consequence but,” Sanyal stated.
Administration characterised the primary half of the yr as unfolding largely as anticipated and stated early lead indicators—notably order consumption—have remained steady. Sanyal emphasised that Varex’s largest end-market publicity is healthcare, the place demand is pushed largely by affected person dynamics slightly than near-term macro occasions. He stated the corporate has not seen impacts on hospital capital budgets, nor has it heard prospects “telegraph” modifications in shopping for habits.
In response to questions concerning the firm’s roughly 70/30 combine between medical and industrial markets, Sanyal stated the medical aspect seems “considerably unaffected” to this point. On the economic aspect, he described non-destructive testing/inspection as additionally unaffected to this point.
On safety functions, nonetheless, Sanyal stated developments seem at the very least “flat to optimistic,” including that the corporate is seeing “extra urgency” and elevated inquiries about its applied sciences.
Sanyal and CFO Sam Maheshwari stated Varex adjusted pricing and pass-through mechanisms after a pointy escalation in tariff ranges earlier within the cycle. Sanyal stated the corporate’s stock elevated for a number of causes, and that reductions in tariff charges haven’t but totally flowed by outcomes as a result of higher-tariff stock stays available.
Maheshwari stated present situations are “directionally optimistic,” however cautioned that ongoing coverage dialogue—together with potential Part 301 actions—might result in additional modifications. He stated Varex continues to mitigate tariff impacts by steps resembling provide chain diversification (together with efforts to diversify extra sourcing out of India), trade-compliance methods, and continued progress towards “local-for-local” manufacturing.
On profitability, Maheshwari stated that if the present tariff regime stays in place, gross margin might enhance modestly as older, higher-tariff stock strikes by the P&L over roughly 4 to 5 months. He estimated the profit at “a number of tens of foundation factors,” citing a attainable 30 to 50 foundation level enchancment, in contrast with a beforehand mentioned 100 to 150 foundation level affect when increased tariffs have been instituted. He added that the corporate is watching what occurs when non permanent tariff measures are changed.
Sanyal stated China’s imaging market dynamics have adopted the corporate’s expectations after a interval that included hospital audits, stimulus results that have been initially complicated, and provide chain distortions from prospects buying too far forward. He stated China stays dedicated to increasing healthcare supply in rural markets, describing a sample the place provinces inspired hospitals with comparatively new methods to exchange them with up to date variations and redeploy displaced methods into rural settings. He referred to as that dynamic “wholesome,” saying it elevated put in base and refreshed methods.
He stated demand now seems “steady to possibly barely rising” and has shifted towards a extra mature replacement-driven sample, slightly than the “frenzied” progress charges seen in prior intervals. He added that secular progress in China stays increased than the two% to three% progress charges usually related to mature markets.
On aggressive positioning, Sanyal stated home Chinese language imaging gamers are successful share in authorities tenders, which he stated have grow to be “extraordinarily aggressive.” He added that this pattern has been favorable for Varex as a result of it provides a lot of these home gamers. Requested about hypothesis that giant international OEMs may exit or promote stakes in China, Sanyal stated the corporate views such commentary as “largely rumour” and didn’t provide a conclusion.
Individually, Sanyal stated he doesn’t see a selected materials-availability concern for Varex akin to helium constraints affecting MRI methods.
Maheshwari offered updates on two India services. He stated the detector facility is full and starting to ramp, with “fairly respectable income” anticipated from India-made detectors within the second half of 2026. On tubes, he stated the manufacturing facility is lower than a yr away from producing product, with preliminary batches anticipated towards the tip of calendar 2026.
He stated each factories are designed round radiographic merchandise, an space the place Varex has had decrease market share because of worth sensitivity. Administration is concentrating on new merchandise manufactured in India to assist acquire share. Maheshwari stated the corporate expects a “considerably linear” progress profile from the start of fiscal 2027 by the tip of fiscal 2028, concentrating on about $100 million of incremental radiographic income over roughly two years, above natural expectations.
On photon-counting CT, Sanyal described adoption as early however stated the expertise has confirmed viable. He stated preliminary deployments have emphasised excessive decision, whereas the longer-term worth is “exact materials discrimination,” together with multi-energy “spectral” imaging. He added that Varex is concentrated on enabling adoption past the most important OEMs and prime tutorial facilities. Searching to 2028, Sanyal stated the corporate’s aim is to have 4 OEMs deeply engaged in design work; he stated Varex has two at the moment and expects extra OEMs within the pipeline, noting the corporate would really feel comfy with three and “excellent” with 4 by the tip of 2028.
Maheshwari reiterated a aim to maneuver company gross margin towards the excessive 30% vary over the following few years, citing three drivers:
Photon counting, which he stated ought to carry gross margins above the company common and carry total margins as adoption grows.
Cargo inspection methods, the place he stated service income is “considerably extra accretive” on margin because the put in base expands.
India radiographic progress, which he stated is anticipated to be nearer to corporate-average gross margin however ought to contribute significant working leverage.
Maheshwari additionally mentioned a latest debt refinancing, saying the corporate diminished coupon charges by about 175 foundation factors, translating to roughly $7 million to $8 million in annual curiosity financial savings, or about $0.15 to $0.16 in annualized EPS profit. He stated the refinancing simplified the steadiness sheet and described the end result as optimistic regardless of uneven markets.
Varex Imaging Company is a worldwide supplier of X-ray imaging parts and options for the medical, safety and industrial markets. The corporate designs, develops and manufactures a broad vary of merchandise that convert X-ray vitality into high-resolution digital photos. Its portfolio consists of X-ray tubes, flat panel detectors, digital sensors, specialty radiographic tubes and associated software program, all engineered to fulfill the demanding necessities of authentic gear producers (OEMs) in diagnostic imaging, computed tomography (CT), fluoroscopy, mammography, dental radiography and non-destructive testing functions.
The corporate’s medical imaging choices help a large spectrum of scientific modalities, from moveable radiography methods to superior CT scanners, enhancing picture high quality and dose effectivity for healthcare suppliers.
